“Experience is something you don’t get until just after you need it.”

Proventus.org.uk

Improving Life - Increasing Hope

 

 

Our booklets of information are provided free to our members

Booklets

 

All contents

© Copyright proventus.org.uk

   

UK Reg charity

No 1108986

 

terms and conditions

 

Helpline

Tel 01233 334 879

 

E-mail enquiries

 

Website Maker

Serif

WEBPLUSX2

Dec 2006

A recent warning from the chair of NICE

Britain's chief drug adviser (NICE) has accused Pharmaceutical Companies of covert and distasteful tactics in funding patient groups that campaign for wider use of the medicines they manufacture.

 

Sir Michael Rawlins, chairman of the National Institute for Health and Clinical Excellence (NICE), which decides which drugs are provided by the NHS, warned that the industry’s sponsorship of Health Charities could lead to excessive pressure and unfair rulings about which medicines were made available.

 

“It is important everybody is aware that a particular patient organisation gets money from the Pharmaceutical Industry and that is not easy to find out at the moment,” Rawlins said. “The patient group may not just receive money: the Pharmaceutical Company may be providing help and resources, such as the use of their PR manager.”

 

Rawlins added: “In the long term it will do the patient organisations an immense amount of damage and the confidence in their neutrality will dissipate. . . It certainly is distasteful.”

 

 

 

NICE has recently come under pressure from some cancer and dementia charities to make new drugs for these illnesses available on the NHS.

 

 

 

“I hope the members of my appraisal committee [at NICE] keep their minds clear but there is always a slight worry that they will be tainted and that he who shouts the loudest gets”, said Rawlins.

 

The Alzheimer’s Society has led a patient campaign against a NICE ruling that the dementia drugs Aricept, Reminyl and Exelon were not cost-effective and should not be paid for from public funds.

 

New figures from the charities show that in the last financial year the Alzheimer’s Society received £31,000 from Pfizer and Eisai, which make Aricept.

 

In the last year the society also received £13,000 from Shire Pharmaceuticals, manufacturer of Reminyl, and £14,000 from Novartis, manufacturer of Exelon.

 

 

 

 

 

 

 

NICE came under pressure this year from Cancer Charities to extend provision of the breast cancer “wonderdrug” Herceptin to women with the disease in its early stage.

 

One of the most vocal charities, Cancerbackup, received £29,000 from Roche, which makes Herceptin.

 

Health Charities insist they have been open about funding from drug companies.

 

 

Full article on the Sunday Times web site written by

 

Sarah Kate Templeton

The Sunday Times Dec 3rd 2006

 

 

 

NICE

The National Institute of Clinical Excellence.

 

____________________

 

March 2007

 

Free Air Conditioning in the UK

 

For those who suffer from serious lung conditions.

 

Chronic Obstructive Pulmonary Disease (COPD) kills approx 30,000 people a year (especially smokers).

 

The Department of Health said the air-conditioning units would be handed out only to people who had a proven clinical need.

 

The units can be prescribed by  a GP, if a COPD sufferer gets bad in hot weather to the point that they may be hospitalised then their GP might provide portable air conditioning.

 

Why not MS people as well?

 

Hot weather is less than helpful to multiple sclerosis people. Ask your GP, let us know their response.

 

Full article by

Sarah-Kate Templeton

The Sunday Times March 4th 2007